Timing arguments in this family generally rest on the assumption that endogenous release is suppressed by circulating glucose and insulin. That is well supported; the practical protocols built on top of it are much less so.
5 likes 24d
Compounds · Secretagogues & GH axis · continued
Secretagogues and glucose tolerance: the mechanistic concern posts 61–71
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Collapsed as off-topic by two members at trust level 3 or above
Research-use-only secretagogues are not approved for human use. That statement is doing real work in this subcategory, where the published evidence base is thinner than the volume of confident discussion.
The short answer was in the first line; everything after is the working.
Narrowing post #61, because the general version has more than one answer.
Adding a reference point for secretagogues and glucose tolerance. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
28 likes 23d
Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or safety profile in humans. That gap is larger for secretagogues than for incretin agonists because the human evidence is thinner.
8 likes 21d
maintenance_mode, post #26: That matches what I have seen, for whatever a single anecdote is worth. Go to post
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
The arithmetic in post #64 is right; the assumption feeding it is the part to check.
Since secretagogues and glucose tolerance keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.
0 likes 20d
Confirming post #68 from a second method, which matters more than confirming it from a second person.
Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established.
Noting that the question and the thing people usually mean by it are different.
13 likes 18d
Nothing to add, except that this is the answer I would give if asked.
27 likes 18d
This topic was referenced in
- Second pass at: Why this subcategory is stricter about sourcing than mostCompounds › Secretagogues & GH axis · 129 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Evidence quality in the secretagogue literature: an honest assessment
On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. A follow-up question about Evidence quality that I did not know to…
|
+20 | 24 | 18k | 4mo |
|
Tesamorelin has an approved indication — what that changes about the evidence
Tesamorelin has an approved indication — what that changes about the evidence — setting out what I have, and where I think it stops being reliable. What changes if the standard account of tesamorelin is…
|
+23 | 27 | 3.4k | 1d |
|
Why pulsatile secretion matters for interpreting secretagogue claims
Why pulsatile secretion matters for interpreting secretagogue claims — that is the question, and I have not found it answered plainly anywhere I have looked. A follow-up question about pulsatile secretion…
|
+5 | 9 | 1.6k | 15h |
|
Reading a rodent study on a secretagogue without over-extrapolating
Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. Reading a rodent study, and specifically the version…
|
+50 | 54 | 32k | 10mo |
|
What a well-designed human trial of a secretagogue would look like
What a well-designed human trial of a secretagogue would look like I have a specific reason for asking rather than idle curiosity, and the context is below. I was wrong about well-designed human trial in a…
|
2 | 7.2k | 18mo |
Related topics — sharing the tags CJC-1295, tesamorelin, observational data
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Reading a preclinical wound-healing model and its relevance to a human tendon
On the subject in the title: Reading a preclinical wound-healing model and its relevance to a human tendon Working notes rather than a conclusion. Posting a small dataset on reading a preclinical…
|
+149 | 160 | 3.3k | 20mo |
|
Sample size in a voluntary survey: the selection problem
Posting this under the heading it deserves: Sample size in a voluntary survey: the selection problem Everything below is what sits behind that. Sample size: setting out the arithmetic in full, because I have…
|
+1 | 5 | 12k | 15mo |
|
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold?
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. The question about Analytical…
|
+28 | 33 | 1.6k | 1mo |
|
Stability of BPC-157 in solution: what has been measured
Stability of BPC-157 in solution: what has been measured — setting out what I have, and where I think it stops being reliable. Something about stability of BPC-157 does not reconcile and I would like a second…
|
2 | 805 | 30d | |
|
Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset
The question in the title: Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset I will give what I have already checked below so nobody repeats it. Posting a small dataset…
|
+60 | 64 | 25k | 15mo |